Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis Provides Update On R&D Pipeline
Sanofi-aventis has provided an update of its R&D pipeline for four of its projects: DuoPlavin in cardiology, Cabazitaxel in oncology, Eplivanserin in insomnia and Idrabiotaparinux in thrombosis. On
Sanofi-aventis has provided an update of its R&D pipeline for four of its projects: DuoPlavin in cardiology, Cabazitaxel in oncology, Eplivanserin in insomnia and Idrabiotaparinux in thrombosis. On
Clinuvel Pharmaceuticals has obtained positive 4-months results in testing Afamelanotide in a multicentre randomised double-blind placebo controlled Phase III study in EPP (CUV017). In 2008, Afamelanotide was awarded
Borealis, a provider of chemical and plastics solutions, has announced its decision to withdraw all activities for the rotomoulding sector by March 31, 2010. Borealis has been committed
Seattle Genetics has entered into a collaboration agreement with GlaxoSmithKline (GSK) under which GSK will pay an upfront fee of $12m for rights to utilize Seattle Genetics’ antibody-drug
Soligenix, formerly known as Dor BioPharma, has initiated a phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of
Neuralstem has reported that its Phase I trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells has been approved by
Ista has submitted a supplemental New Drug Application (sNDA) to the FDA for bromfenac ophthalmic solution as a treatment for ocular inflammation and pain following cataract surgery. Ista
Boehringer Ingelheim and Pfizer have received FDA approval for Spiriva HandiHaler (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
The United States Patent and Trademark Office (USPTO) has determined that US Patent No. 6444673, which is a composition of matter patent that covers Sepracor’s human drug product,
Ambit Biosciences (Ambit) and Astellas Pharma (Astellas) have entered into a worldwide agreement to jointly develop and commercialise FLT3 kinase inhibitors in oncology and non-oncology indications. The partnership